Target Name: GHR
NCBI ID: G2690
Other Name(s): mutant growth hormone receptor | GHIP | GHR variant 1 | Serum binding protein | Growth hormone receptor (isoform 1) | V2 | GH receptor | Somatotropin receptor | Serum-binding protein | Growth hormone binding protein | truncated growth hormone receptor | serum binding protein | growth hormone receptor | Growth hormone receptor | Growth hormone-binding protein | GHR_HUMAN | GH-binding protein | growth hormone binding protein | Growth hormone receptor (GHR) | Growth hormone receptor, transcript variant 1 | somatotropin receptor | GHBP

GHR Mutations and Their Implications for Disease Treatment

GHR (Growth Hormone Receptor) is a protein that is found on the surface of most cells in the body. It is a key regulator of cell growth and development, and is involved in the formation and maintenance of tissues such as muscle, bone, and fat. Mutations in the GHR gene have been linked to a variety of diseases, including growth hormone resistance, a condition that can cause muscle weakness and wasting in children with growth hormone deficiency.

GHR mutations can also be a drug target for researchers, as they can be used to develop new treatments for diseases that are caused by changes in GHR function. One of the most promising areas of research is the use of GHR inhibitors to treat conditions that are Characterized by overactive muscle growth, such as muscle cancer and myopathies. These drugs would work by blocking the activity of the GHR protein, which would inhibit the formation of new muscle cells and reduce muscle growth.

Another area of 鈥嬧?媟esearch that is being explored is the use of GHR inhibitors to treat conditions that are characterized by abnormal muscle development, such as neuromuscular junction disease. These conditions are characterized by the fusion of muscle and nerve cells, and the resulting muscle growth can be abnormal and can cause weakness and other symptoms. GHR inhibitors have been shown to be effective in treating these conditions, and are currently being tested in clinical trials.

In addition to its potential as a drug target, GHR is also being studied as a biomarker for various diseases. For example, GHR levels are often elevated in muscles of children with growth hormone deficiency, and levels are also often elevated in muscles of individuals with myopathies. These observations suggest that GHR may be a useful biomarker for these diseases, and that levels of GHR may be a useful diagnostic tool for these conditions.

Overall, GHR is a complex and important protein that is involved in the regulation of cell growth and development. Its role in the treatment of various diseases is being explored, and research into its potential as a drug and biomarker is ongoing. As research continues, GHR is likely to play an increasingly important role in the understanding and treatment of a wide range of diseases.

Protein Name: Growth Hormone Receptor

Functions: Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity)

More Common Targets

GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1 | GKN1 | GKN2 | GKN3P | GLA | GLB1 | GLB1L | GLB1L2 | GLB1L3 | GLC1C | GLCCI1 | GLCCI1-DT | GLCE | GLDC | GLDN | GLE1 | GLG1 | GLI1 | GLI2 | GLI3 | GLI4 | GLIDR | GLIPR1 | GLIPR1L1 | GLIPR1L2 | GLIPR2 | GLIS1 | GLIS2 | GLIS3 | GLIS3-AS1 | GLMN | GLMP | GLO1 | GLOD4 | GLOD5 | GLP1R | GLP2R | GLRA1 | GLRA2 | GLRA3